Sadness and anxiety are natural reactions to approaching death. However, sometimes these symptoms reach the significant intensity and are associated with the development of a depressive episode in people at the end of life. Diagnosis of depression may mean that somatic symptoms of advanced disease are subject to exacerbation due to the mental condition (reduced pain threshold, fatigue, sleep disorders, reduced appetite). Depressive patients will be less likely to cooperate in treatment, which may lead to deterioration of overall health, worse prognosis and higher mortality. It seems, therefore, that pharmacotherapy of depression in end-of-life patients should not be marginalized. However, due to antidepressants' delayed onset of action most patients probably fail to achieve satisfactory improvement on time. We propose as the first target for the treatment of depression in palliative care a fast and safe reduction of symptoms. Without giving up the basic antidepressant treatment, expected risk and benefits should be carefully and individually considered before the inclusion of standard medications, especially in terms of remaining life expectancy. We also believe that, if started, such pharmacotherapy should often be accompanied by medications that can quickly alleviate at least some depression symptoms making it easier for the patient to wait for the beneficial effect of the drug. Focusing on the rapid improvement of mental state, mianserin, mirtazapine, pregabalin, quetiapine, trazodone and vortioxetine seem to be beneficial for use in palliative care. Med Pract 2019; 13, 2: 82-89 
Introduction
Sadness and anxiety are natural reactions to approaching death. However, sometimes these symptoms reach the significant intensity and are associated with the development of a depressive episode in people at the end of life [1] . Prevalence of depression is usually estimated at 15% of patients undergoing palliative care [2] with a range of 4-58% [3] .
In end-of-life patients establishing a diagnosis may be difficult due to the possibility of overlapping of depressive symptoms with symptoms of somatic illness or treatment's side effects [4] . Furthermore, in this situation clinical scales and self-assessment questionnaires have limited use due to numerous questions about the somatic status and future perception, which, judged by the patient subjectively, may indicate the presence of depression, where none is present. When a diagnosis of depression in a patient requiring palliative care is confirmed, this may mean that somatic symptoms of advanced disease are subject to exacerbation due to the mental condition (reduced pain threshold, fatigue, sleep disorders, reduced appetite) [5] . Depressive patients will be less likely to cooperate in treatment, which will lead to deterioration of overall health condition, worse prognosis and higher mortality [6] .
The best method of preventing and alleviating depressive symptoms is to ensure proper conditions of functioning for patients at the end of life in the form of adequate palliative care, with studies showing depressive symptoms prevalence in patients undergoing palliative care at 16% with 38% in people who did not receive such care [7] . As it is not always an achievable goal, it seems that pharmacotherapy of depressive disorder in end-of-life patients should not be marginalized.
Pharmacotherapy of depression
In some cases, a significant reduction of depressive symptoms takes weeks to months of antidepressant (AD) administration [8] . Remission after monotherapy is reached by only 25-35% of patients [9] , while the therapeutic response to treatment (reduction of depressive symptoms by at least 50%) is observed in 1/3 of patients during first pharmacotherapy attempt [10] . In a large, multicenter STAR*D [10] study, it was shown that after a year of antidepressant treatment with four consecutive ADs, where each was used for 12 weeks in therapeutic doses, only 2/3 of patients achieved remission. All the above data concern the whole group of depressive patients, both healthy and burdened in terms of somatic disease. In palliative care, several worse prognosis and treatment resistance risk factors need to be considered. These include old age (average age over 70 in stationary hospices) [11] , adverse life situation, co-existing somatic diseases, institutionalization (in the case of treatment in a residential hospice) [12] .
According to the STAR*D [10] study mentioned above, we can expect remission in 56% of patients after two treatment attempts (about 12 weeks, or 84 days). Taking into account unfavourable prognosis and the fact that about one-third of patients discontinue AD during the first month of therapy [13] , the expected remission rate in end-of-life patients will probably be significantly lower. In view of the data that the average time of care for adults in a hospice is 29 days (with a median 12 days) [11] , and 38 days (median 18 days) in the home hospice care [14] as well as publications indicating that 76% of patients started antidepressant treatment during the last two weeks of life [15] , it should be recognized that most patients will fail to achieve satisfactory improvement using the most commonly used AD, such as tricyclic antidepressants (TCA), selective serotonin reuptake inhibitors (SSRI), and selective serotonin and noradrenaline reuptake inhibitors. (SNRI), where neurophysiological mechanisms of action are revealed after 3-4 weeks at the earliest [16] . Furthermore, it is possible that in the first period of therapy patients will experience only somatic and psychological side effects (anxiety, anxiety, abdominal pain, headaches, palpitations, loss of appetite) [17] , which may additionally worsen the patient's condition at the end of life.
With the efficacy of ADs in palliative care being beyond doubt, as confirmed by Rayner et al. meta-analysis [18] , there is a prominent time-dependent effect with the largest odds ratio of treatment response observed after 9-18 weeks of treatment. While TCA show significantly greater efficacy than SSRI, it should be taken into account that their use in patients under palliative care should be limited due to numerous side effects (including cholinolytic) and delayed onset of action [19] [20] [21] .
Another issue that needs to be addressed is a common practice of prescribing drugs from the benzodiazepine group or "Z drugs" to patients with depressive symptoms [22] . According to available data, up to 36% of patients with the depressive disorder receive drugs from the above-mentioned groups [23] . Apart from the addictive potential [24, 25] , these substances have a number of side effects and may lead to disturbed sleep architecture, orthostatic pressure drops, amnesia or increased daytime sleepiness among others [25, 26] . Despite their evident efficacy in reducing anxiety and sleep disorders, they seem to be useful only in immediate help while their use should be strictly limited in patients with advanced diseases.
Current standards of pharmacotherapy at the end of life do not point towards any single AD [20] as the first choice for treatment of the major depressive disorder (MDD). The most commonly used and recommended medications are mirtazapine, sertraline and (es-) citalopram [27] . In view of the above-mentioned arguments, we propose as the first target for the treatment of depression in palliative care a fast and safe reduction of symptoms. Without giving up the basic antidepressant treatment, we believe that the expected risk and benefits should be carefully and individually considered before the inclusion of ADs from the TCA, SSRI or SNRI group, especially in terms of remaining life expectancy. We also believe that, if started, such pharmacotherapy should often be accompanied by medications that can quickly alleviate at least some depression symptoms making it easier for the patient to wait for the beneficial effect of the drug [28] .
Rapid reduction in the symptoms of depression
Focusing on the rapid improvement of mental state, mianserin, mirtazapine, pregabalin, quetiapine, trazodone and vortioxetine seem to be beneficial for use in palliative care. The following are brief characteristics of drugs along with their specificity in the use of end-of-life patients.
Mianserin and Mirtazapine
Despite different molecule structure, these two drugs have a very similar receptor profile, which translates into similar effects and side effects [29] . Both are AD with a strong hypnotic and anxiolytic activity, which may appear even before the target effect of treatment, although the effect is rarely revealed after a single dose [30] . According to Rayner's et al. meta-analysis mentioned above [18] , the efficacy of mianserin and mirtazapine in patients at the end of life is even higher than that of TCA at similar time intervals. The value of the above data is weakened by a small number of subjects in the former group.
The neurophysiological profile of the drugs is dose-dependent. Hypnotic effect appearing at lower doses mianserin or mirtazapine can be eliminated by increasing the dose to activate noradrenergic pathway [31, 32] , which may be useful in case of excessive sedation at low doses of drugs.
Administration of these substances in palliative care can also result in a rapid improvement of appetite, although it will not always be physiological. It is frequently observed that patients on mianserin or mirtazapine wake up at night to urgently eat foods with high sugar content [33] . Mirtazapine also has a pronounced antiemetic effect, which can significantly improve the patients' well-being at the end of life, especially in the case of neoplastic disease [34] . Another advantage is the possibility of relatively safe combination with SSRI or SNRI drugs to augment or supplement treatment [35] .
The main disadvantage of the above drugs is often the difficulty in achieving therapeutic doses due to intense side effects, mainly associated with sedation, increased appetite, restless legs syndrome, or in the case of mianserin with either a direct cholinolytic effect or a possibility of augmentation of other drugs' cholinolytic effects, which, in extreme cases, may lead to delirium [36] [37] [38] . Physicians who use these medications in palliative care should bear in mind possible complications of treatment in the form of bone marrow suppression (neutropenia) and excessive water retention in the body (edema) [36, 39, 40] . Hypertension may be observed with higher doses as a result of noradrenergic pathway activation [41] . Mirtazapine also increases the risk of bleeding [42] and serotonin syndrome [43] . Moreover, these AD should not be combined with other sleeping and sedating drugs without clear indications for such treatment [44] .
Pregabalin
Pregabalin is an analogue of gamma-aminobutyric acid (GABA) that acts on calcium channels in the CNS [45] . This drug may not have direct antidepressant activity, but its use results in a rapid improvement of sleep and reduction of anxiety in patients [46] . Additionally, in palliative care, it can also be used to support analgesia and to reduce somatic symptoms of anxiety [47] .
Pregabalin may temporarily exacerbate depressive symptoms and suicidal thoughts [48] , but an improvement in mood is observed more frequently if the reason for its lowering was anxiety. Risk of addiction, although being a rather background issue in palliative care, should be taken into account, especially in the context of expected longer treatment [49] . History of addictions, especially opiate dependency, is a predisposing factor to the development of tolerance [50] . Combination of the drug with benzodiazepines and other drugs acting through GABA receptors as well as with oxycodone should be avoided. Especially the latter combination seems to be important due to the possible impact on cognitive functions and large motor skills [51] .
It seems that the use of pregabalin should be limited to the situation when the dominant symptoms are anxiety and pain or when the prospect of chronic treatment remains questionable. With presumed long-term treatment, pregabalin may be considered as a drug added to basic antidepressant therapy [52] and should never be used in monotherapy.
Quetiapine
Quetiapine is an atypical antipsychotic drug with dose-and form-dependent effect [53] . Its mechanism of action is through numerous neurotransmission systems in the central nervous system (CNS): serotoninergic, noradrenergic and adrenergic among others. It also has antihistamine, cholinolytic and dopamine blocking activity [54] . At lowest doses, it works only as a hypnotic. With the gradual increase other effects appear: anxiolytic, antidepressant, mood stabilizing and antipsychotic (doses above 400 mg) [55] . In the treatment of anxiety and depression, it proved effective to use the extended release (XR) form in doses of 150-300 mg [56] , possibly supplemented with low (12.5-50 mg) doses of the fast-acting form to improve sleep [57] . However, due to the numerous side effects (severe decreases in blood pressure, sedation), it is necessary to gradually and slowly increase the dose [58] . Improvement in sleep may occur after a single dose [59, 60] , the anxiolytic effect usually appears after a few days [61] , while the antidepressant action requires a longer time [62] . When administering the drug in palliative care patients, clinicians should also pay attention to the risk of QTc prolongation and a significant impact on the metabolism resulting in worsening of glucose tolerance [63, 64] .
Despite evidence for efficacy both in monotherapy [65] and polytherapy [66] of MDD, quetiapine's registration for depressive disorder in the U.S. is only as an adjunctive treatment to conventional antidepressants. In Poland, regulations allow for its use in schizophrenia and bipolar disorder with additional refund policy for patients with neuropsychiatric disorders associated with dementia. Administration of quetiapine in patients with MDD or anxiety disorders is off-label, therefore lower doses (not exceeding 200mg) and special care are suggested, should this drug be considered.
Trazodone
Trazodone is an antidepressant with dose-dependent effect, which results directly from the characteristics of the receptor's profile (blocks serotonin 5HT2A, adrenergic and histamine receptors, and inhibits serotonin reuptake in synaptic gaps). Low doses (25-75 mg) have a hypnotic and sedative activity, medium -anxiolytic and high (300 mg and more) -antidepressant [67, 68] .
Administrating trazodone may result in rapid improvement of sleep, reduction of anxiety and restlessness [69] . The antidepressive efficacy was compared to the efficacy of TCA in one the study [70] . Appropriate use of two available forms of trazodone seems to be the key to beneficial use of the substance. Chronic release (CR) form is more sedative in the first hours after administration with extended release (XR) form maintaining a constant concentration of the drug within 24 hours [71] . It is permissible to combine two forms, for instance by achieving antidepressant doses with the XR form (thus avoiding excessive sedation) with an auxiliary sleep regulation with small doses of the CR form [72] .
Sleep induced by trazodone has physiological features [73] . Consequently, its quality is clearly higher than that following administration of benzodiazepines or hypnotics from the so-called "Z-drugs" group (zolpidem, zopiclone, zaleplon and derivatives). Furthermore, the use of trazodone does not carry the risk of addiction or deterioration of sexual functioning [74, 75] . The main limitation is excessive morning sedation [36] , although sometimes it is a result of the drug being taken too late the night before (less than two hours before bedtime). Attention should also be paid to accompanying cardiac diseases due to an increased risk of cardiac conduction and rhythm disturbances [76] .
Vortioxetine
One of the most recently registered AD widely modulates neurotransmission in the CNS directly through serotonin receptors, and indirectly through other pathways [77] . It is considered one of the fastest-acting AD with first effects that can be seen after two weeks of therapy [78] . Despite proven anxiolytic properties, it seems that the drug is more activating in nature, especially in the first period of use, which may translate into a lack of sleep-regulating or anxiolytic effect during this period, and consequently no improvement felt by the patient until the antidepressant effect of the drug is activated [79, 80] . It may be reasonable to combine it with one of the above-mentioned drugs that have a more significant sedative effect.
The beneficial effect of vortioxetine on cognitive functions [81] and the lack of sexual dysfunctions during therapy [82] is also raised. Vortioxetine is well-tolerated, and in a recent Lancet meta-analysis by Cipriani et al. [83] it was recognized as the drug with the most favorable ratio of effectiveness to safety. High therapy cost is the main limitation in the wider use of this substance.
Ketamine and S-Ketamine
Ketamine is an antagonist of N-Methyl-D-aspartic acid (NMDA) initially used as an anesthetic characterized by a specific effect of dissociative anaesthesia [84] . Currently, ketamine and ketamine's S-enantiomer are studied for efficacy and safety in the treatment of depression with very promising first results [85, 86] . Both drugs seem to be also effective in treatment-resistant depression leading to immediate improvement, especially after intravenous administration [87] . This effect appears even 4 hours after the infusion and lasts at least a week [88] . Subsequent doses of the drug may cause the stabilization of the antidepressant effect to an average of 18 days [89] . Nevertheless, many serious side effects were noted, including cardiac, neurological, urological and psychiatric [90] .
The use of intravenous infusions of ketamine would require constant supervision and care with expected exceptional but relatively short-lived effects, which makes it a possible future option of treatment in stationary hospices. S-ketamine, currently under studies as a nasal spray for daily use, could greatly facilitate administration of this drug should it be approved by the FDA.
Conclusions
Despite the existence of several guidelines [20, 91, 92] , AD pharmacotherapy in patients undergoing palliative care carries a lot of challenges and uncertainties resulting from a shortage of data [93] and still insufficient awareness of the needs of people at the end of life. With the view that the administration of benzodiazepines and "Z-drugs" should be limited, we suggest that rapid-acting properties of other drugs may also be used to alleviate depressive symptoms in patients at end of life. It is however essential, that standard AD care is not left out and the rule of "start low, go slow" apply to therapy initiation, so that patients' safety is not at risk. Additional care should be put when off-label medications are applied and their doses up-titrated. Further studies on the efficacy and safety of drugs with potential for reducing at least some depressive symptoms in patients at end of life are required. 
Streszczenie
Smutek i lęk są naturalnymi reakcjami na zbliżającą się śmierć, czasami jednak objawy te osiągają znaczne nasilenie i wiążą się z rozwojem epizodu depresyjnego u chorego u kresu życia. Potwierdzenie rozpoznania depresji u pacjenta wymagającego opieki paliatywnej może oznaczać, że duża część objawów somatycznych zaawansowanej choroby podlega zaostrzeniu ze względu na stan psychiczny (obniżony próg bólu, zmęczenie, zaburzenia snu, obniżone łaknienie). Chorzy depresyjni będą gorzej współpracować w leczeniu, co będzie się przekładać na ich mniejszą ogólną sprawność, gorsze rokowanie i większą śmiertelność. Wydaje się więc, że podjęcie farmakoterapii depresji u chorych u kresu życia nie powinno być marginalizowane. Z powodu opóźnionego początku działania leków przeciwdepresyjnych większość pacjentów prawdopodobnie nie osiągnie zadowalającej poprawy na czas. Wobec tego jako pierwszy cel leczenia depresji w opiece paliatywnej proponuje się koncentrację na szybkiej i bezpiecznej redukcji objawów. Oczekiwane ryzyko i korzyści podstawowego leczenia przeciwdepresyjnego należy starannie i indywidualnie rozważyć przed włączeniem leków, zwłaszcza biorąc pod uwagę oczekiwany czas życia pacjenta. Nie zaniechując takiej terapii, autorzy uważają, że ewentualnemu jej rozpoczęciu często powinny towarzyszyć leki, które mogą szybko złagodzić przynajmniej niektóre objawy depresji, ułatwiając pacjentowi oczekiwanie na korzystne działanie terapii podstawowej. W odniesieniu do szybkiej poprawy stanu psychicznego, kwetiapina, mianseryna, mirtazapina, pregabalina, trazodon i wortioksetyna wydają się być najkorzystniejszym wyborem.
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Wstęp
Smutek i lęk są naturalnymi reakcjami na zbliżającą się śmierć, czasami jednak objawy te osiągają znaczne nasilenie i wiążą się z rozwojem epizodu depresyjnego u chorego u kresu życia [1] . Zazwyczaj szacuje się, że depresja występuje u 15% pacjentów poddawanych opiece paliatywnej [2] , przy zakresie 4-58%, w zależności od badania [3] .
Postawienie rozpoznania zaburzeń depresyjnych u chorego u kresu życia może jednak nastręczać trudności wynikających z możliwości nakładania się objawów depresyjnych z objawami choroby somatycznej lub z działaniami niepożądanymi stosowanego
